title: Studies of catecholamine metabolism in schizophrenia/psychosis--II.
abstract: Acutely psychotic schizophrenic patients were maintained on debrisoquin (DBQ) throughout 5 weeks of treatment with haloperidol. Treatment with haloperidol caused initial increases in urinary homovanillic acid (HVA) output that returned toward baseline by the 5th week. During haloperidol treatment, plasma levels of HVA tended to decrease, concurrent with increased renal clearance of HVA. Plasma 3-methoxy-4-hydroxyphenylglycol (MHPG) levels and urinary MHPG output both decreased over the course of treatment. The differences in HVA and MHPG metabolism suggest differential effects of treatment on dopamine and norepinephrine systems. Neuroleptic treatment also abolished the marked morning decreases in plasma HVA concentrations (reported in part I).
authors: Department of Psychiatry, University of Texas Health Science Center, San Antonio 78284-7792.
authors: J W
authors: JW
authors: Maas
authors: S A
authors: SA
authors: Contreras
authors: A L
authors: AL
authors: Miller
authors: N
authors: N
authors: Berman
authors: C L
authors: CL
authors: Bowden
authors: M A
authors: MA
authors: Javors
authors: E
authors: E
authors: Seleshi
authors: S E
authors: SE
authors: Weintraub
mesh_terms: D000328:Adult; D000368:Aged; D000704:Analysis of Variance; D002395:Catecholamines / Q000378:metabolism*; D002940:Circadian Rhythm / Q000502:physiology; D006220:Haloperidol / Q000627:therapeutic use; D006719:Homovanillic Acid / Q000378:metabolism; D006801:Humans; D008297:Male; D008734:Methoxyhydroxyphenylglycol / Q000378:metabolism; D008875:Middle Aged; D012559:Schizophrenia / Q000188:drug therapy / Q000378:metabolism* / Q000503:physiopathology
chemical_list: D002395:Catecholamines; D008734:Methoxyhydroxyphenylglycol; D006220:Haloperidol; D006719:Homovanillic Acid